Immunoglobin From Chinese Maker Involved In Six Deaths
This article was originally published in PharmAsia News
A batch of immunoglobin produced by Jiangxi Yabo Biopharmaceutical of China may have caused of the deaths of six hospital patients. Health authorities ordered sales and use of the JYBC immunoglobin suspended and urged the firm to recall the entire batch. In addition, local authorities sealed all JYBC immunoglobin until samples can be tested. The injections were given during the past week at a Nanchang University-affiliated hospital in East China. (Click here for more
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.